News | April 26, 2021
Lonza will invest CHF 200 mn to construct manufacturing complex
New manufacturing complex will occupy an overall footprint of approximately 2,000 square meter with six levels of manufacturing space
New manufacturing complex will occupy an overall footprint of approximately 2,000 square meter with six levels of manufacturing space
Lonza's Ibex Design end-to-end offering will cover the development stages of IMT-009 from development candidates through early clinical studies
The company will add a single-use assembly production unit at its Life Science Center in Molsheim, France.
Applied Biosystems CoviPath COVID-19 RT-PCR Kit is approved for in vitro diagnostic use by ICMR and DCGI.
The medical device Sector in India suffers from a considerable cost of manufacturing disability.
Lonza maintained business continuity during the COVID-19 pandemic with minimal impacts to operations and supply throughout 2020.
The company is expecting tremendous growth and a better quarterly performance
The Phase 2 study of Sputnik V was conducted on 100 subjects as part of the randomized, double-blind, parallel-group, placebo-controlled study in India.
Their feedback and the consequent changes in software/protocols based on those inputs were deliberated upon.
Subscribe To Our Newsletter & Stay Updated
